Blame Drew's Cancer
Drew Olanoff is a young California man diagnosed with Stage III Hodgkin's Lymphoma who has taken a decidedly 21st century approach to fighting his cancer: using the viral nature of the internet in a big way.
He's started a web site, blamedrewscancer.com where you can go and blame whatever the hell you want on Drew's cancer. Step in a pile of dog crap this morning? Blame Drew's cancer. Blow a date? Blame Drew's cancer. Get fired? Blame Drew's cancer. Have an itch you can't reach? Blame Drew's Cancer.
But you have to blame his cancer in a certain way. On Twitter, if you mention "#BlameDrewsCancer" in a Tweet, the organizations Drew has sponsoring his fight will make a donation to the American Cancer Society and the Make-a-Wish Foundation.
So far on Twitter, 8,264 people have blamed 14,697 things on Drew's cancer. Personally, I just became the 8,265th person; I blamed Drew's cancer for my bad hair day.
If you're on Facebook, check out his causes page.
Drew's a pretty clever guy. Before he even knew he had cancer, he put up for auction on Twitter a part of his body on which the winning Twitter bidder could have their name tattooed. The winning bidder was $2,112, all of which he gave to the Make-a-Wish Foundation.
Rock on Drew: Your cancer sucks. Your angle rules.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
